The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
Site Search
Showing 21 - 30 of 71 results
News
|
May 4, 2009
|
2 min read
News
|
Dec. 15, 2009
|
2 min read
News
|
Feb. 20, 2009
|
2 min read
News
|
Dec. 28, 2007
|
2 min read
News
|
Dec. 28, 2007
|
1 min read
News
|
Aug. 7, 2018
|
3 min read
Tezacaftor/ivacaftor (Symdeko™) is approved for individuals with two copies of the most common cystic fibrosis mutation, F508del, as well as for individuals who have a single copy of one of 26 specified mutations -- regardless of their other mutation.
News
|
Feb. 12, 2018
|
4 min read
Celtaxsys Inc. reported promising results today from an early stage clinical trial of a potential anti-inflammatory drug for people with cystic fibrosis.
News
|
Aug. 2, 2018
|
2 min read
News
|
May 24, 2010
|
2 min read
With a record 45 clinical trials either ongoing or starting up in 2016, research coordinators and principal investigators throughout the Therapeutics Development Network took time out in San Antonio recently to discuss clinical research and put attendees through boot camp.
Patty Burks, M.A., RN, CCRC
|
3 min read